Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension

被引:1
|
作者
Zhang, Jingsi [1 ]
Wang, Mingyu [1 ]
Sun, Kehui [1 ]
Ding, Yanchun [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dept Cardiol 2, Dalian, Peoples R China
关键词
ACEI; ARB; primary hypertension; renal dynamic imaging; split renal function; KIDNEY-DISEASE; BLOOD-PRESSURE; IRBESARTAN; MORTALITY;
D O I
10.1097/MD.0000000000025928
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bilateral kidney damage in hypertensive patients is not parallel. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), as a commonly used antihypertensive drug, could protect kidney function and delay its deterioration. Most studies focused on overall renal function, but the researches on split renal function (SRF) are rare. We investigated the effects of ACEI/ARB on the SRF in patients with primary hypertension. Patients with primary hypertension (n = 429; male: 213; female: 216) admitted to our department between January 2014 and December 2016 were included in this study. The glomerular filtration rate (GFR) of split and total renal function were determined using diethylenetriaminepentaacetic acid tagged with 99mTc renal dynamic imaging method. For the same patient, the side with high GFR was considered as higher GFR kidney, whereas that with a low GFR was considered as lower GFR kidney. The split function score (Q value) was utilized to evaluate the differences of bilateral renal function. The patients were divided into 3 groups based on the Q values (Group 1, Q value <5%; Group 2, Q value of 5%-10%; Group 3, Q value >= 10%). All the patients received antihypertensive therapy based on ACEI/ARB. The renal dynamic imaging was performed in the 1-year follow-up to investigate the changes of the SRF. Compared with the baseline level, significant decline was noticed in the serum creatinine (Scr) in Group 2 and Group 3 (P < .05). The cystatin C in Group 3 showed significant decline (P < .05). Compared with the baseline, there was significant decline in the Q value in Group 2, whereas the GFR of lower GFR kidney showed significant increase (P < .05). No statistical differences were noticed in the Q value and split GFR in Group 1 and Group 3 (P > .05). In primary hypertension patients, ACEI/ARB therapy could improve the SRF of lower GFR kidney in the presence of certain differences between the SRF. As a result, the SRF difference was reduced. In case of Q value in a range of 5% to 10%, ACEI/ARB could improve the renal function effectively. It may be significant for the design of antihypertensive drugs.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] ANGIOTENSIN-CONVERTING ENZYME INHIBITORS VERSUS ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTS WITH HYPERTENSION
    Sanchez, Andres M. Cordova
    Shmorgon, Gary
    Olonoff, Danielle A.
    Ramm, Matthew
    Gualan, Carlos Merino
    Chaudhuri, Debanik
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2074 - 2074
  • [22] Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function
    Morimoto, Satoshi
    Maki, Kei
    Aota, Yasuko
    Sakuma, Takao
    Iwasaka, Toshiji
    HYPERTENSION RESEARCH, 2008, 31 (08) : 1603 - 1610
  • [23] Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
    Lee, Hyun Woo
    Suh, Jae Kyung
    Jang, Eunjin
    Lee, Sang-Min
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, 36 (02): : 371 - 381
  • [24] Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function
    Moriyama, Takahito
    Amamiya, Nobuyuki
    Ochi, Ayami
    Tsuruta, Yuki
    Shimizu, Ari
    Kojima, Chiari
    Itabashi, Mitsuyo
    Takei, Takashi
    Uchida, Keiko
    Nitta, Kosaku
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2011, 15 (05) : 700 - 707
  • [25] Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function
    Takahito Moriyama
    Nobuyuki Amamiya
    Ayami Ochi
    Yuki Tsuruta
    Ari Shimizu
    Chiari Kojima
    Mitsuyo Itabashi
    Takashi Takei
    Keiko Uchida
    Kosaku Nitta
    Clinical and Experimental Nephrology, 2011, 15 : 700 - 707
  • [26] Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
    Hasvold, L. P.
    Bodegard, J.
    Thuresson, M.
    Stalhammar, J.
    Hammar, N.
    Sundstrom, J.
    Russell, D.
    Kjeldsen, S. E.
    JOURNAL OF HUMAN HYPERTENSION, 2014, 28 (11) : 663 - 669
  • [27] Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
    Boenner, G.
    Bakris, G. L.
    Sica, D.
    Weber, M. A.
    White, W. B.
    Perez, A.
    Cao, C.
    Handley, A.
    Kupfer, S.
    JOURNAL OF HUMAN HYPERTENSION, 2013, 27 (08) : 479 - 486
  • [28] Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention
    Ann, Soe Hee
    Strauss, Martin H.
    Park, Gyung-Min
    Han, Seungbong
    Yang, Yujin
    Kim, Yong-Giun
    Won, Ki-Bum
    Kim, Shin-Jae
    Lee, Sang-Gon
    Cho, Young-Rak
    Kim, Dae-Won
    Park, Mahn-Won
    Her, Sung Ho
    Lee, Seung-Whan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 35 - 41
  • [29] TOTAL AND SPLIT RENAL-FUNCTION IN PATIENTS WITH RENOVASCULAR HYPERTENSION - EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION
    REAMS, GP
    SINGH, A
    LOGAN, KW
    HOLMES, RA
    BAUER, JH
    JOURNAL OF CLINICAL HYPERTENSION, 1987, 3 (02): : 153 - 163
  • [30] Comparison of anti hypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy
    Stergiou, GS
    Makris, T
    Papavasiliou, M
    Efstathiou, S
    Manolis, A
    JOURNAL OF HYPERTENSION, 2005, 23 (04) : 883 - 889